BBC News

Blood cancer therapy reverses incurable leukaemia in some patients

NEJM

Nejmoa2505478

Metaculus

Stirling News

Innovative therapy gives hope to patients whose blood cancer seemed incurable

Medicalxpress

2025 12 Ready Cell Gene Therapy Tackles.Html

The Standard

News Medical

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Sky News

Patients with previously untreatable blood cancer now disease-free after world-first gene therapy

Independent

At 13, I thought my leukaemia was incurable. But a new treatment has made me cancer-free

Pioneering new treatment reverses incurable blood cancer in some patients

The Times of India

World-first gene therapy reverses 'incurable' leukemia in some patients

Blood Journals Portfolio

Universal Base Edited Car7 T Cells For T Cell

A clinical trial involving nine children and two adults with T-cell acute lymphoblastic leukemia at Great Ormond Street Hospital and King's College Hospital showed that 82% of patients achieved "deep remission" after receiving BE-CAR7 treatment, enabling them to proceed to stem cell transplant without detectable disease.

A clinical trial involving nine children and two adults with T-cell acute lymphoblastic leukemia at Great Ormond Street Hospital and King's College Hospital showed that 82% of patients achieved "deep remission" after receiving BE-CAR7 treatment, enabling them to proceed to stem cell transplant without detectable disease.

The BE-CAR7 therapy uses base editing technology to modify healthy donor T-cells through three key DNA changes: disabling existing receptors to make them universal, removing the CD7 marker to prevent self-destruction and adding a chimeric antigen receptor to target cancerous T-cells.

The BE-CAR7 therapy uses base editing technology to modify healthy donor T-cells through three key DNA changes: disabling existing receptors to make them universal, removing the CD7 marker to prevent self-destruction and adding a chimeric antigen receptor to target cancerous T-cells.

Alyssa Tapley from Leicester, who was 13 when she became the first patient to receive the base-edited treatment in 2022, is now 16 and disease-free, with plans to pursue an apprenticeship in biomedical science and eventually work in blood cancer research.

Alyssa Tapley from Leicester, who was 13 when she became the first patient to receive the base-edited treatment in 2022, is now 16 and disease-free, with plans to pursue an apprenticeship in biomedical science and eventually work in blood cancer research.

The treatment showed that 64% of patients remain disease-free, with some patients now three years post-treatment and off medication. Side effects, including low blood counts, cytokine release syndrome and rashes, were reported as manageable by researchers.

The treatment showed that 64% of patients remain disease-free, with some patients now three years post-treatment and off medication. Side effects, including low blood counts, cytokine release syndrome and rashes, were reported as manageable by researchers.

Base editing is an advanced form of CRISPR technology that changes single letters of DNA code without cutting the DNA strand, reducing the risk of chromosomal damage while allowing scientists to precisely modify the genetic instructions within living cells.

Base editing is an advanced form of CRISPR technology that changes single letters of DNA code without cutting the DNA strand, reducing the risk of chromosomal damage while allowing scientists to precisely modify the genetic instructions within living cells.

The researchers say the new treatment is for those who do not respond to standard therapies. This discovery was published in the New England Journal of Medicine on Monday and presented at the 67th American Society of Hematology Annual Meeting.

The researchers say the new treatment is for those who do not respond to standard therapies. This discovery was published in the New England Journal of Medicine on Monday and presented at the 67th American Society of Hematology Annual Meeting.

BBC News #

NEJM #

Metaculus #

Stirling News #

Medicalxpress #

The Standard #

News Medical #

Sky News #

Independent #

AOL #

The Times of India #

MSN #

Blood Journals Portfolio #

The BE-CAR7 therapy uses base editing technology to modify healthy donor T-cells through three key DNA changes: disabling existing receptors to make them universal, removing the CD7 marker to prevent self-destruction, and adding a chimeric antigen receptor to target cancerous T-cells.

The BE-CAR7 therapy uses base editing technology to modify healthy donor T-cells through three key DNA changes: disabling existing receptors to make them universal, removing the CD7 marker to prevent self-destruction, and adding a chimeric antigen receptor to target cancerous T-cells.

The treatment showed that 64% of patients remain disease-free, with some patients now three years post-treatment and off medication, though side effects including low blood counts, cytokine release syndrome and rashes were reported as manageable by researchers.

The treatment showed that 64% of patients remain disease-free, with some patients now three years post-treatment and off medication, though side effects including low blood counts, cytokine release syndrome and rashes were reported as manageable by researchers.

The researchers say the new treatment is for those who do not respond to standard therapies. This groundbreaking discovery was published in the New England Journal of Medicine and presented at the 67th American Society of Hematology Annual Meeting.

The researchers say the new treatment is for those who do not respond to standard therapies. This groundbreaking discovery was published in the New England Journal of Medicine and presented at the 67th American Society of Hematology Annual Meeting.

Gene-edited therapy BE-CAR7 represents a monumental breakthrough in cancer treatment, achieving 82% deep remission rates for previously incurable T-cell leukemia. This off-the-shelf treatment uses base editing to transform donor immune cells into cancer-fighting weapons, offering real hope where only palliative care existed before.

Gene-edited therapy BE-CAR7 represents a monumental breakthrough in cancer treatment, achieving 82% deep remission rates for previously incurable T-cell leukemia. This off-the-shelf treatment uses base editing to transform donor immune cells into cancer-fighting weapons, offering real hope where only palliative care existed before.

While BE-CAR7 shows promise, the reality remains sobering: only 64% of patients remain disease-free, and outcomes were not as hoped for some children in these intense, difficult treatments. The therapy requires wiping out the entire immune system, leaving patients vulnerable to life-threatening infections during recovery.

While BE-CAR7 shows promise, the reality remains sobering: only 64% of patients remain disease-free, and outcomes were not as hoped for some children in these intense, difficult treatments. The therapy requires wiping out the entire immune system, leaving patients vulnerable to life-threatening infections during recovery.

There is a 50% chance the average survival rate of all cancers will exceed 75% by Dec. 2030, according to the Metaculus prediction community.

There is a 50% chance the average survival rate of all cancers will exceed 75% by Dec. 2030, according to the Metaculus prediction community.

Craig T Fruchtman/Contributuor/Getty Images

Gene-Edited Therapy Achieves 82% Remission in Leukaemia Trial

Health

Medicine & healthcare

Science & technology

Diseases & conditions

While this may indeed offer promise, it could also face sobering long-term limits. Even though 82% of patients reached deep remission, unintended effects from gene-editing and immune-manipulation remain substantial. The “off-the-shelf” edited T-cells carry risks such as prolonged immunosuppression, infections, marrow suppression and in some cases immune escape of leukemia via CD7-negative variants — meaning relapse may still occur.

While this may indeed offer promise, it could also face sobering long-term limits. Even though 82% of patients reached deep remission, unintended effects from gene-editing and immune-manipulation remain substantial. The “off-the-shelf” edited T-cells carry risks such as prolonged immunosuppression, infections, marrow suppression and in some cases immune escape of leukemia via CD7-negative variants — meaning relapse may still occur.

There is a 50% chance that the average survival rate of all cancers will exceed 75% by December 2030, according to the Metaculus prediction community.

There is a 50% chance that the average survival rate of all cancers will exceed 75% by December 2030, according to the Metaculus prediction community.

Gene-Edited Therapy Achieves 82% Remission in Leukemia Trial

Gene-Edited Therapy Achieves 82% Remission in LeukaemiaLeukemia Trial

The Spin

Metaculus Prediction

Articles on this story

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters